rhabdomyosarcoma (Cancer)
Information
- Disease name
- rhabdomyosarcoma
- Disease ID
- DOID:3247
- Description
- "A skeletal muscle cancer that arise from skeletal muscle progenitors." [url:http\://en.wikipedia.org/wiki/Rhabdomyosarcoma, url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425116/]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| IRS2 | 13 | 109,752,695 | 109,786,583 | 4 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02567435 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | June 1, 2016 | October 1, 2024 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT02945800 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | October 25, 2016 | December 2024 |
| NCT02076906 | Active, not recruiting | Phase 1 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | April 2014 | November 24, 2024 |
| NCT02867592 | Active, not recruiting | Phase 2 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | May 18, 2017 | September 21, 2024 |
| NCT03462888 | Active, not recruiting | Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients | February 2, 2018 | December 2024 | |
| NCT03220035 | Active, not recruiting | Phase 2 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | November 8, 2017 | September 22, 2024 |
| NCT03478462 | Active, not recruiting | Phase 1 | Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | April 30, 2019 | December 2024 |
| NCT05302921 | Active, not recruiting | Phase 2 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | February 18, 2022 | July 1, 2025 |
| NCT01858168 | Active, not recruiting | Phase 1 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | July 2013 | December 2024 |
| NCT02415816 | Active, not recruiting | N/A | Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas | June 5, 2015 | April 2027 |
| NCT01871766 | Active, not recruiting | Phase 2 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | December 4, 2013 | June 2030 |
| NCT00186992 | Active, not recruiting | Phase 2 | Radiation Therapy to Treat Musculoskeletal Tumors | January 10, 2003 | October 2024 |
| NCT04095221 | Active, not recruiting | Phase 1/Phase 2 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | September 17, 2019 | September 2024 |
| NCT03709680 | Active, not recruiting | Phase 1/Phase 2 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | May 24, 2019 | February 25, 2025 |
| NCT05093322 | Completed | Phase 1/Phase 2 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | November 30, 2021 | April 25, 2023 |
| NCT04956198 | Completed | Drug Sensitivity and Mutation Profiling | November 17, 2020 | December 31, 2022 | |
| NCT01125800 | Completed | Phase 1/Phase 2 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | February 2011 | October 2014 |
| NCT01169584 | Completed | Phase 1 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | August 2010 | November 2014 |
| NCT01241162 | Completed | Phase 1 | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | August 2010 | October 2016 |
| NCT01331135 | Completed | Phase 1 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | April 2011 | August 9, 2017 |
| NCT01336803 | Completed | Phase 2 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI | August 2011 | October 2023 |
| NCT01355445 | Completed | Phase 2 | Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma | January 2012 | May 2019 |
| NCT01386619 | Completed | Phase 1/Phase 2 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | January 2004 | March 2011 |
| NCT01505569 | Completed | N/A | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | October 20, 2011 | February 1, 2024 |
| NCT01614795 | Completed | Phase 2 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | June 18, 2012 | April 1, 2014 |
| NCT01625351 | Completed | Phase 1 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | August 20, 2012 | February 10, 2020 |
| NCT01661400 | Completed | Phase 1 | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors | October 26, 2012 | December 27, 2023 |
| NCT01674101 | Completed | N/A | Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | September 2012 | November 2015 |
| NCT04854018 | Completed | Phase 4 | Indo-cyanine Green (ICG) in Paediatric Oncology MIS | April 30, 2021 | September 30, 2022 |
| NCT01962103 | Completed | Phase 1/Phase 2 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | December 4, 2013 | November 6, 2018 |
| NCT02048371 | Completed | Phase 2 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | July 2014 | May 2022 |
| NCT02100891 | Completed | Phase 2 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | March 20, 2013 | July 15, 2020 |
| NCT02162732 | Completed | N/A | Molecular-Guided Therapy for Childhood Cancer | July 8, 2014 | January 18, 2024 |
| NCT02239861 | Completed | Phase 1 | TAA-Specific CTLS for Solid Tumors (TACTASOM) | April 2015 | April 7, 2022 |
| NCT02372006 | Completed | Phase 1/Phase 2 | Trial of Afatinib in Pediatric Tumours | April 29, 2015 | August 5, 2020 |
| NCT02390843 | Completed | Phase 1 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | February 2015 | September 22, 2019 |
| NCT00001335 | Completed | Phase 2 | New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | April 1993 | January 2002 |
| NCT00004853 | Completed | Phase 1 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | March 3, 2000 | May 20, 2009 |
| NCT02509598 | Completed | Phase 2 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | August 2015 | March 6, 2019 |
| NCT02890758 | Completed | Phase 1 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | May 22, 2018 | February 17, 2023 |
| NCT02982941 | Completed | Phase 1 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | December 2016 | May 22, 2019 |
| NCT03245450 | Completed | Phase 1/Phase 2 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | March 5, 2018 | May 17, 2021 |
| NCT00187109 | Completed | Phase 1/Phase 2 | Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy | June 2000 | February 2007 |
| NCT00187174 | Completed | Phase 1 | Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors | October 2004 | October 2008 |
| NCT00354835 | Completed | Phase 3 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma | December 26, 2006 | December 31, 2022 |
| NCT00436657 | Completed | Phase 1 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | February 2007 | April 2011 |
| NCT00464620 | Completed | Phase 2 | Trial of Dasatinib in Advanced Sarcomas | May 2007 | May 2017 |
| NCT00520936 | Completed | Phase 2 | A Study of Pemetrexed in Children With Recurrent Cancer | September 2007 | February 2010 |
| NCT00001564 | Completed | Phase 2 | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | December 23, 1996 | October 25, 2007 |
| NCT00668148 | Completed | Phase 2 | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma | July 2008 | February 2012 |
| NCT00001566 | Completed | Phase 2 | A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas | December 1996 | September 2008 |
| NCT00001686 | Completed | Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases | March 19, 1998 | September 2, 2020 | |
| NCT00919269 | Completed | Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma | March 15, 1999 | September 30, 2023 | |
| NCT00931931 | Completed | Phase 1 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | March 2010 | March 19, 2018 |
| NCT03655587 | Completed | N/A | Impact of an Orthotic Intervention in Children With Peripheral Neuropathy | September 20, 2016 | May 18, 2022 |
| NCT03054792 | Enrolling by invitation | Phase 1 | Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas | May 1, 2017 | December 2024 |
| NCT06198296 | Not yet recruiting | Phase 1 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | January 1, 2026 | February 1, 2043 |
| NCT04890093 | Not yet recruiting | Phase 1/Phase 2 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | June 23, 2024 | December 31, 2026 |
| NCT06029465 | Not yet recruiting | Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials | October 2024 | October 2026 | |
| NCT04715191 | Not yet recruiting | Phase 1 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | July 3, 2024 | July 3, 2041 |
| NCT04337177 | Recruiting | Phase 1 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | October 25, 2021 | June 2024 |
| NCT00592592 | Recruiting | Phase 2 | Proton RT for the Treatment of Pediatric Rhabdomyosarcoma | October 2004 | August 2025 |
| NCT00840047 | Recruiting | Phase 2 | Methionine PET/CT Studies In Patients With Cancer | July 20, 2009 | July 27, 2027 |
| NCT00898755 | Recruiting | Collecting and Storing Tissue From Young Patients With Cancer | March 5, 2007 | ||
| NCT02508038 | Recruiting | Phase 1 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | February 12, 2016 | December 2025 |
| NCT03050268 | Recruiting | Familial Investigations of Childhood Cancer Predisposition | April 6, 2017 | March 31, 2037 | |
| NCT03496402 | Recruiting | N/A | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) | April 20, 2018 | August 19, 2027 |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT04299113 | Recruiting | Phase 1 | Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | May 14, 2020 | May 22, 2026 |
| NCT04308330 | Recruiting | Phase 1 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | March 17, 2017 | December 31, 2024 |
| NCT04377932 | Recruiting | Phase 1 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | December 8, 2021 | February 1, 2040 |
| NCT04388839 | Recruiting | Phase 2 | Evolutionary Therapy for Rhabdomyosarcoma | September 27, 2020 | December 2027 |
| NCT04625907 | Recruiting | Phase 1/Phase 2 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | September 17, 2020 | June 2030 |
| NCT04791228 | Recruiting | Phase 2 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | November 10, 2022 | December 1, 2025 |
| NCT04796012 | Recruiting | Phase 1/Phase 2 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | April 18, 2023 | January 2025 |
| NCT04897321 | Recruiting | Phase 1 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | July 6, 2022 | March 1, 2027 |
| NCT04995003 | Recruiting | Phase 1 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | December 7, 2021 | December 31, 2040 |
| NCT05103631 | Recruiting | Phase 1 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | June 17, 2021 | December 2039 |
| NCT05697198 | Recruiting | PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine | April 19, 2021 | September 2024 | |
| NCT06023641 | Recruiting | Phase 1/Phase 2 | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | March 13, 2024 | October 2037 |
| NCT06094101 | Recruiting | Phase 1/Phase 2 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) | September 19, 2023 | September 2027 |
| NCT06456892 | Recruiting | Phase 1/Phase 2 | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen | June 6, 2024 | December 6, 2026 |
| NCT02536183 | Terminated | Phase 1 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | October 2016 | October 2022 |
| NCT00428272 | Terminated | Phase 1 | HGS-ETR2 to Treat Children With Solid Tumors | December 4, 2006 | October 9, 2015 |
| NCT03458728 | Terminated | Phase 1/Phase 2 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | April 30, 2018 | February 1, 2023 |
| NCT02624388 | Terminated | Phase 2 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | August 2016 | September 2021 |
| NCT04730349 | Terminated | Phase 1/Phase 2 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | June 3, 2021 | June 22, 2022 |
| NCT02581384 | Terminated | Phase 1/Phase 2 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | January 2017 | August 2020 |
| NCT03041701 | Terminated | Phase 1/Phase 2 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | July 7, 2017 | October 16, 2021 |
| NCT00162695 | Terminated | Phase 3 | Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood | July 1995 | |
| NCT02409576 | Unknown status | Phase 1/Phase 2 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas | February 2015 | September 2020 |
| NCT01807468 | Unknown status | Phase 2 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | May 2013 | June 2019 |
| NCT00339118 | Unknown status | Phase 4 | EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children | ||
| NCT02013336 | Unknown status | Phase 1 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | December 2013 | December 2023 |
| NCT00944580 | Withdrawn | Phase 1 | A Vaccine Study for High Risk Cancers | June 2009 | August 2010 |
| NCT05116800 | Withdrawn | Phase 2 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | March 1, 2022 | August 2030 |
| NCT02689336 | Withdrawn | Phase 2 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | August 6, 2016 | May 31, 2020 |
| NCT01697514 | Withdrawn | Phase 1 | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma | July 2013 | July 2016 |
| NCT02557854 | Withdrawn | Phase 1 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | December 2016 | March 16, 2019 |
| NCT04906876 | Withdrawn | Phase 2 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | September 2021 | July 2025 |
| NCT01112800 | Withdrawn | Markers of Anthracycline-Related Cardiac Muscle Injury | May 2010 | January 2013 | |
| NCT02011126 | Withdrawn | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | June 30, 2014 |
- Disase is a (Disease Ontology)
- DOID:4043
- Cross Reference ID (Disease Ontology)
- ICDO:8900/3
- Cross Reference ID (Disease Ontology)
- MESH:D012208
- Cross Reference ID (Disease Ontology)
- NCI:C3359
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:302847003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0035412
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002859
- OrphaNumber from OrphaNet (Orphanet)
- 780
- MeSH unique ID (MeSH (Medical Subject Headings))
- D012208